<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[RSS Feed]]></title><description><![CDATA[RSS Feed]]></description><link>http://direct.ecency.com</link><image><url>http://direct.ecency.com/logo512.png</url><title>RSS Feed</title><link>http://direct.ecency.com</link></image><generator>RSS for Node</generator><lastBuildDate>Sun, 10 May 2026 19:36:13 GMT</lastBuildDate><atom:link href="http://direct.ecency.com/created/hotstock/rss.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[오늘의 상한가 주식 [ 승일, 049830 주식투자 ]]]></title><description><![CDATA[상한가란 전거래일 대비 최대가능 상승폭인 +30% 상승한 가격을 말합니다. 30일 오전 코스닥 상장기업중 유일하게 상한가를 기록한 종목은 승일 (049830)입니다. 전거래일인 27일 주식 1주당 1만원에 장을 마감한 승일의 주가는 30일 오전 30% 상승한 13,000원에 거래매매가 진행되고 있습니다. 장 시작 9분만에 상한가를 기록하였는데요 거래량은 1백만주도채]]></description><link>http://direct.ecency.com/kr/@jyinvest/049830</link><guid isPermaLink="true">http://direct.ecency.com/kr/@jyinvest/049830</guid><category><![CDATA[kr]]></category><dc:creator><![CDATA[jyinvest]]></dc:creator><pubDate>Mon, 30 Jul 2018 01:46:03 GMT</pubDate><enclosure url="https://images.ecency.com/p/2H74Fic92U9jgyxqbDwFDr3rHbp474i3Lft22aERzFefkQpCCPAEANtK46LjgCUxQZyUeeZr26PTDCXkGWN7FmsQuxT9WmJpEL4T8AjDo1UUocj57EsrwujU2yGUtFdUecMHmwrKuopH3KdvaBHXY9CycQLRqBcfZkSnmnyaw2oSuw4np1HbmmQ8GmDJpckjYer6hhtRLSkwWfCVL9JCKqhVjKZGwsr5kwwdSUACfZsMft71UVE7v2QnKBKk?format=match&amp;mode=fit" length="0" type="false"/></item><item><title><![CDATA[Biofrontera, Opportunities After FDA Approval]]></title><description><![CDATA[Summary Ameluz (nano emulsion) is superior to former formulation Levulan (actinic kreatoses) and Metvix (basal cell carcinoma). FDA approval for Ameluz as treatment for basal cell carcinoma is likely to]]></description><link>http://direct.ecency.com/biotech/@s1241003/biofrontera-opportunities-after-fda-approval</link><guid isPermaLink="true">http://direct.ecency.com/biotech/@s1241003/biofrontera-opportunities-after-fda-approval</guid><category><![CDATA[biotech]]></category><dc:creator><![CDATA[s1241003]]></dc:creator><pubDate>Sun, 29 Apr 2018 11:52:15 GMT</pubDate></item><item><title><![CDATA[Co.Don; Spherox A Tissue Engineering Product With German Quality Standard]]></title><description><![CDATA[Summary Co.don is a German company with over 20 years of experience. Leading manufacturer of autologous cell therapies for the treatment of cartilage defects. Spherox can repair cartilage defects of the]]></description><link>http://direct.ecency.com/stock/@s1241003/co-don-spherox-a-tissue-engineering-product-with-german-quality-standard</link><guid isPermaLink="true">http://direct.ecency.com/stock/@s1241003/co-don-spherox-a-tissue-engineering-product-with-german-quality-standard</guid><category><![CDATA[stock]]></category><dc:creator><![CDATA[s1241003]]></dc:creator><pubDate>Sun, 22 Apr 2018 20:57:06 GMT</pubDate></item><item><title><![CDATA[look to buy onvo]]></title><description><![CDATA[Organovo Holdings gets FDA orphan drug status for 3D biprinted therapeutic liver tissue treatment of alpha-1 antitrypsin deficiency...]]></description><link>http://direct.ecency.com/money/@ndstocktrader/look-to-buy-onvo</link><guid isPermaLink="true">http://direct.ecency.com/money/@ndstocktrader/look-to-buy-onvo</guid><category><![CDATA[money]]></category><dc:creator><![CDATA[ndstocktrader]]></dc:creator><pubDate>Tue, 26 Dec 2017 19:28:51 GMT</pubDate></item></channel></rss>